Previous 10 | Next 10 |
EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the H.C. Wainwright BioConnect Investor Confere...
EMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the commercial payment and a portion of the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus Pharmaceuticals for the control...
2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Org...
EMERYVILLE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the 43 rd Annual Cowen Health Care Conf...
EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, the Company’s newly appointed Executive Chairman, two separate n...
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Jim Neal has retired as Chief Execu...
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales milestones Low- to mid- teens royal...
XOMA press release ( NASDAQ: XOMA ): Q3 GAAP EPS of -$0.48 misses by $0.25 . Revenue of $0.5M (-44.4% Y/Y) misses by $4.02M . Research and development (“R&D”) expenses were $29,000 and $30,000, respectively, for the third quarters of 2022 an...
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million c...
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-06-04 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...